In Brief: Cortecs/Osteometer BioTech agreement
This article was originally published in The Gray Sheet
Executive Summary
Cortecs/Osteometer BioTech agreement: U.K.-based oral drug delivery firm Cortecs inks a development deal with Danish diagnostics firm Osteometer BioTech A/S to develop a whole blood, point-of-care diagnostic product for the detection of collagen breakdown, an indicator of osteoporosis. Cortecs, calling the deal a "profit-sharing agreement," says that the development effort will combine its rapid diagnostic technologies with Osteometer's Cross-laps bone resorption marker technology. The companies will jointly develop the product, with clinical testing coordinated by The Center for Clinical and Basic Research in Denmark. Cortecs will manufacture the finished product, retain distribution rights for the U.K. and Australia and select distributors for other markets "from international corporations involved in the management of osteoporosis"...